Construction and Preclinical Evaluation of a
iodine isotope
mesothelin
positron emission tomography
radioimmunoimaging
scFv-Fc
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
2
5
2020
medline:
8
6
2021
entrez:
2
5
2020
Statut:
ppublish
Résumé
Mesothelin is a molecular biomarker of many types of solid cancers, which may represent a highly promising new target in the development of cancer-targeted diagnostic agents. A human anti-mesothelin antibody with a low molecular weight, ET210sc, was applied; this antibody has potent affinity and can penetrate tissue quickly and stably without causing immunoreactions. We developed a new
Identifiants
pubmed: 32356995
doi: 10.1021/acs.molpharmaceut.9b01281
doi:
Substances chimiques
GPI-Linked Proteins
0
Iodine Isotopes
0
Msln protein, mouse
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM